Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1023-1030

  Burke, James P ^a   Sander, Stephen ^b   Shah, Hemal ^b   Zarotsky, Victoria ^a   Henk, Henry ^a  

^a i3 Innovus   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Adherence; Antiplatelet therapy; Persistence; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE;

ADULT; ANTIPLATELET THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG COST; DRUG FORMULATION; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PREDICTIVE VALIDITY; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; DIPYRIDAMOLE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; STROKE; SURVIVORS; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951041538     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003670563     Document Type: Article

References (26)

1. Rosamond W, Flegal K, Furie K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics 2008 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117:e25-46. Available at: http://circ.ahajournals.org/cgi/content/full/117/4/e25 [Last accessed 20 January 2010]
2. Carswell JL, Beard KA, Chevrette MM, et al. Tracking trends in secondary stroke prevention strategies. Ann Pharmacother 2004;38:215-219
3. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute, 2006
4. Samsa GP, Bian J, Lipscomb J, et al. Epidemiology of recurrent cerebral infarction: a Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:338-349
5. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke. Stroke 2004;35:1925-1929
6. Lovett JK, Dennis MS, Sandercock PAG, et al. Very early risk of stroke after a transient ischemic attack. Stroke 2003;34:e138-40
7. Coull AJ, Lovett JK, Rothwell PM. Oxford Vascular Study. Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328:326-328
8. Shaya FT, El Khoury AC, Mullins CD, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006;12:313-319
9. National Stroke Association. Secondary (Recurrent) Risk. Available at: http://www.stroke.org/site/PageServer?pagenameRECUR [Last accessed 20 January 2010]
10. Antithrombotic Trialists' Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86
11. Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients follow prescriptions for medications. Cochrane Database Syst Rev 2000; 2:CD000011
12. Johnson P, Rosewell M, James MA. How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy? Cerebrovasc Dis 2007;23:156-161
13. Wang Y, Wu D, Wang Y, et al. A survey on adherence to secondary ischemic stroke prevention. Neurol Res 2006;28:16-20
14. Zusman RM. Clinical and economic implications of atherosclerosis. Manag Care 2000;9:1-4
15. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/ Downloads/HIPAALaw.pdf [Last accessed 20 January 2010]
16. Tirschwell DL, Longstreth Jr WT. Validating administrative data in stroke research. Stroke 2002;33:2465-2470
17. Clinical Classifications Software (CCS) for ICD-9-CM. Available at: http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp [Last accessed 20 January 2010]
18. Sappok T, Faulstich A, Stuckert E, et al. Adherence with secondary prevention of ischemic stroke: a prospective evaluation. Stroke 2001;32:1884-1889
19. Hamann GF, Weimar C, Glahn J, et al. German Stroke Data Bank. Adherence to secondary stroke prevention strategies: results from the German Stroke Data Bank. Cerebrovasc Dis 2003;15:282-288
20. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501
21. Albers GW, Easton JD, Sacco RL, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998;114:683S-98S
22. Levine DA, Safford MM, Allison JJ, et al. Long-term use of secondary stroke prevention therapies among US veterans. 2008 International Stroke Conference, New Orleans, Louisiana, February 20-22, 2008
23. Gencheva E, Sloan M, Leurgans S, et al. AAASPS Investigators Attrition and non-compliance in secondary stroke prevention trials. Neuroepidemiology 2004;23:61-66
24. Mochari H, Ferris A, Adigopula S, et al. Cardiovascular disease knowledge, medication adherence, and barriers to preventive action in a minority population. Prev Cardiol 2007;10:190-195
25. Chisholm MA, Vollenweider LJ, Mulloy LL, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000;70:1240-1244
26. Buckalew LW, Buckalew NM. Survey of the nature and prevalence of patients' noncompliance and implications for intervention. Psychol Rep 1995;76:315-321